LEADER 04734nam 2200637 450 001 9910643263703321 005 20230213211705.0 010 $a1-283-57215-X 010 $a9786613884602 010 $a0-470-71988-5 010 $a0-470-71754-8 035 $a(CKB)1000000000688099 035 $a(EBL)703830 035 $a(OCoLC)811488085 035 $a(SSID)ssj0000715407 035 $a(PQKBManifestationID)11404022 035 $a(PQKBTitleCode)TC0000715407 035 $a(PQKBWorkID)10703145 035 $a(PQKB)11368059 035 $a(MiAaPQ)EBC703830 035 $a(EXLCZ)991000000000688099 100 $a20160812h19721972 uy 0 101 0 $aeng 135 $aur|n|---||||| 181 $ctxt 182 $cc 183 $acr 200 00$aOntogeny of acquired immunity /$fCiba Foundation 210 1$aAmsterdam, [Netherlands] ;$aLondon, [England] ;$aNew York, New York :$cAssociated Scientific Publishers,$d1972. 210 4$dİ1972 215 $a1 online resource (284 p.) 225 1 $aCiba Foundation Symposium 300 $aDescription based upon print version of record. 311 $a0-470-66293-X 311 $a90-219-4005-1 320 $aIncludes bibliographical references at the end of each chapters and index. 327 $aOntogeny of Acquired Immunity; Contents; Contributors; Introduction; 1 What Precedes Clonal Selection?; THE CLONAL SELECTION THEORY; THE ANTIBODY REPERTOIRE; THE AVAILABLE REPERTOIRE; REPERTOIRE SUPPRESSION; SOURCE OF THE REPERTOIRE; BOUNDARY CONDITIONS; References; Discussion; References; 2 Immunological maturation in the foetus: modulation of the pathogenesis of congenital infectious diseases; ONTOGENESIS OF THE IMMUNE RESPONSE; IMMUNOLOGICAL SUPPRESSION OF PATHOGENICITY; THE IMMUNOLOGICAL ACTIVATION OF PATHOGENlClTY; THE IMMUNOLOGICAL MODULATION OF PATHOGENESIS 327 $aIMMUNOLOGICAL TOLERANCE IN CONGENITAL INFECTIONSUMMARY; ACKNOWLEDGEMENTS; References; Discussion; References; 3 The origins and development of lymphocyte populations; EMBRYONIC HAEMOPOIESIS: DEFINITION, DERIVATION, POTENTIALITIES AND NATUREOF STEM CELLS; LYMPHOPOIESlS IN THE CHICK EMBRYO; SUMMARY; References; Discussion; THETA SPECIFICITY; FUNCTIONAL DIFFERENCES AMONG T CELLS; ANTI-RECEPTOR ANTIBODIES; References; 4 Ontogeny of components of complement and lysozyme; COMPLEMENT; LYSOZYME; SUMMARY; ACKNOWLEDGEMENTS; References; Discussion; References; 5 Allotype suppression 327 $aALLOTYPE SUPPRESSION IN HETEROZYGOTESALLOTYPE SUPPRESSION IN HOMOZYGOTES; CHARACTERISTICS OF ALLOTYPE SUPPRESSION; SUMMARY; References; Discussion; References; 6 Development of cellular immunocompetence in man; BLASTOGENIC RESPONSE OF FOETAL LYMPHOCYTES TO PHA; PHA-MEDIATED LYMPHOCYTOTOXICITY BY HUMAN FOETAL LYMPHOCYTES; DEVELOPMENT OF THE ROSETTE-FORMING CELL IN THE HUMAN FOETUS; SUMMARY; ACKNOWLEDGEMENTS; References; Discussion; References; 7 The role of serum factors ('blocking antibodies') as mediators of immunological non-reactivity to cellular antigens 327 $a'BLOCKING ANTIBODIES' TO TUMOUR-ASSOCIATED (SPECIFIC) ANTIGENSEVIDENCE FOR 'BLOCKING ANTIBODIES' IN PREGNANT MICE; BLOCKING SERUM ACTIVITY IN MICE 'TOLERANT' OF ALLOGRAFTS; WHAT IS THE NATURE OF THE BLOCKING FACTORS AND HOW DO THEY ACT?; SUMMARY; ACKNOWLEDGEMENTS; References; Discussion; References; 8 Concerning the uterus as a graft site and the foetus as a natural parabiotic organismic homograft; ANALYSIS OF THE UTERUS AS A GRAFT SITE; STUDIES ON THE IMMUNOLOGICAL CONSEQUENCES OF A PUTATIVE NATURAL MATERNAL-FOETAL TRANSMISSION OF CELLS IN RATS; DISCUSSION; SUMMARY; ACKNOWLEDGEMENT 327 $aReferencesDiscussion; References; 9 Bone marrow transplantation in a genetically determined anaemia in the mouse; EXPERIMENTS IN NEONATAL MICE; EXPERIMENTS IN ADULT MICE; DISCUSSION; SUMMARY; ACKNOWLEDGEMENTS; References; Discussion; References; 10 Genetic deficiencies of the complement system; GENETIC DEFICIENCIES OF COMPLEMENT COMPONENTS; DEFICIENCY OF COMPLEMENT INHIBITORS; ACKNOWLEDGEMENTS; References; Discussion; References; 11 Defects in immunological development in man; AETIOLOGICAL CONSIDERATIONS; SUMMARY; References; Discussion; References 327 $a12 Treatment of immune deficiency disease with bone marrow stem cell concentrates 410 0$aCiba Foundation symposium. 606 $aImmunity$vCongresses 615 0$aImmunity 676 $a616.07/9 676 $a616.079 712 02$aCiba Foundation. 712 12$aSymposium on Ontogeny of Acquired Immunity 801 0$bMiAaPQ 801 1$bMiAaPQ 801 2$bMiAaPQ 906 $aBOOK 912 $a9910643263703321 996 $aOntogeny of acquired immunity$93005017 997 $aUNINA